- Meeting abstract
Case report: short time reversible myocardial dysfunction in sepsis treated with drotrecogin alpha
Critical Care volume 7, Article number: P24 (2003)
Severe sepsis is a complex process that involves a number of host immune responses with an orchestration of various specific and nonspecific soluble factors and cellular elements that may result in a completely different outcome. Among organ dysfunction induced by sepsis, heart failure can occur in up to 40% of cases . Myocardial depression in shock probably was first described in 1947 . Its onset may be extremely early, but is most evident in the first 3 days of the disease. Normalization usually happens over the following 7-10 days in the survivor patients . We have described an atypical sort time reversible myocardial dysfunction, in a patient with rapid evolution to a multiple organ dysfunction syndrome (heart, renal, pulmonary, and hematological). An 87-year-old man with hypertension and diabetes mellitus type 2 was admitted to our intensive care unit (ICU) with severe sepsis caused by community-acquired pneumonia. On the following day of his ICU entrance he developed septic shock which was associated with an increase in the cardiac enzymes, particularly troponin I and CK mass (fluorogen immunoassay). We started the infusion of Xigris®, a recombinant version of human activated protein C, according to the PROWESS  protocol. His baseline examination characteristics before and 3 days after Xigris® infusion are summarized in Table 1.
The patient was discharged 10 days after the Xigris® end-of-infusion to a step-down unit. The physiology of the myocardial dysfunction that occurs in systemic inflammatory response syndrome is not well understood, although there are several theories to explain it [5–8]. We are reporting an unusual behavior of reversible nonischemic myocardial dysfunction possibly related to Xigris® treatment. Perhaps this communication could be tested in a well-designed study to address a new hypothesis for new applications of activated protein C outside the setting of severe sepsis.
Fernandes CJ, Akamine N, Knobel E: Cardiac troponin: a new serum marker of myocardial injury in sepsis. Intensive Care Med 1999, 25: 1165-1168. 10.1007/s001340051030
Wiggers CJ: Myocardial depression in shock. A survey of cardio dynamic studies. Am Heart J 1947, 33: 633-650. 10.1016/0002-8703(47)90079-3
Parker MM, Shelhamer JH, et al.: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984, 100: 483-490.
Bernard G, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344: 699. 10.1056/NEJM200103083441001
Ungureanu-Longrois D, et al.: Myocardial contractile dysfunction in systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide sintetase in cardiac myocytes. J Moll Cell Cardiol 1995, 27: 155.
Parrillo JE, et al.: A circulating myocardial depressant substance in human with septic shock. J Clin Invest 1985, 76: 1539.
Reilly JM, et al.: A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion in patients with septic shock. Chest 1989, 95: 1072.
Kumar A, et al.: Tumor necrosis factor alpha and interleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996, 183: 949. 10.1084/jem.183.3.949
About this article
Cite this article
Costa-Filho, R., Costa, F., Gomes, P. et al. Case report: short time reversible myocardial dysfunction in sepsis treated with drotrecogin alpha. Crit Care 7, P24 (2003). https://doi.org/10.1186/cc2220
- Intensive Care Unit
- Diabetes Mellitus Type
- Severe Sepsis
- Organ Dysfunction
- Systemic Inflammatory Response Syndrome